Authors

• Dilki Wickramarachchi
• Vitalina Dzutseva (ORCID: https://orcid.org/0000-0002-5630-755X)
• Levin Mj
• John L. Perez
• Odile Launay
• Audrey Sharbaugh
• Taylor S. Cohen (ORCID: https://orcid.org/0000-0001-9368-0903)
• Bernard Veekmans
• Alexandre Kiazand (ORCID: https://orcid.org/0000-0002-3749-1291)
• James G. Sullivan
• Mark Vishnepolsky
• Katie L. Streicher (ORCID: https://orcid.org/0000-0003-1684-2301)
• Mark T. Esser
• Jesse Thissen
• Lee-Jah Chang
• Stephane De Wit
• Meng Li
• Lauren Hirao
• Rohini Beavon
• Huixia Zhang
• Seth Seegobin
• Tommy Rampling
• Priyantha Wijewardane
• Andrew Ustianowski
• Yousef Fawadleh

Institutions

• AstraZeneca (United Kingdom) (GB)
• Université Libre de Bruxelles (BE)
• University College London Hospitals NHS Foundation Trust (GB)
• Inserm (FR)
• Université Paris Cité (FR)
• North Manchester General Hospital (GB)
• Assistance Publique – Hôpitaux de Paris (FR)
• Baptist Health Foundation (US)
• AstraZeneca (France) (FR)
• Birmingham VA Medical Center (US)
• AstraZeneca (Switzerland) (CH)
• AstraZeneca (Poland) (PL)
• Kidney Associates (US)
• DaVita Clinical Research (United States) (US)
• AstraZeneca (Canada) (CA)
• AstraZeneca (United States) (US)
• Centre Hospitalier Universitaire de Saint-Pierre (BE)
• University College London (GB)
• University of Colorado Denver (US)

Publication Details

Journal

Clinical Drug Investigation

Published

2026-01-16

DOI

https://doi.org/10.1007/s40261-025-01515-x

Primary Topic

SARS-CoV-2 and COVID-19 Research

Type

article

Field-Weighted Citation Impact

0.00

Funders

• AstraZeneca